Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
Natera (NASDAQ: NTRA) has expanded its patent infringement lawsuit against NeoGenomics by adding U.S. Patent No. 11,319,596 to the case. The District Court for the Middle District of North Carolina granted Natera's request on December 10, 2024. The amended complaint now includes both the '596 and previously asserted '454 patents, claiming infringement by NeoGenomics' modified RaDaR® test for molecular residual disease. This legal action follows earlier court decisions in December 2023 and September 2024 that resulted in preliminary and permanent injunctions against NeoGenomics' previous version of the RaDaR® test. Natera is pursuing full remedies, including injunctive relief, against NeoGenomics' current RaDaR® test offering.
Natera (NASDAQ: NTRA) ha ampliato la sua causa per violazione di brevetto contro NeoGenomics aggiungendo il Brevetto U.S. n. 11,319,596 al caso. Il Tribunale Distrettuale per il Distretto Centrale della Carolina del Nord ha accolto la richiesta di Natera il 10 dicembre 2024. Il reclamo emendato include ora sia il brevetto '596 che il brevetto '454 precedentemente sostenuto, denunciando la violazione da parte del test modificato RaDaR® di NeoGenomics per la malattia residua molecolare. Questa azione legale segue le precedenti decisioni del tribunale nel dicembre 2023 e nel settembre 2024, che hanno portato a ingiunzioni preliminari e permanenti contro la versione precedente del test RaDaR® di NeoGenomics. Natera sta perseguendo rimedi completi, inclusa la tutela cautelare, contro l'offerta attuale del test RaDaR® di NeoGenomics.
Natera (NASDAQ: NTRA) ha ampliado su demanda por infracción de patente contra NeoGenomics al agregar la Patente de EE. UU. No. 11,319,596 al caso. El Tribunal de Distrito para el Distrito Medio de Carolina del Norte concedió la solicitud de Natera el 10 de diciembre de 2024. La demanda enmendada ahora incluye tanto la patente '596 como la patente '454 previamente presentada, alegando infracción por parte de la prueba modificada RaDaR® de NeoGenomics para la enfermedad residual molecular. Esta acción legal sigue a decisiones judiciales anteriores en diciembre de 2023 y septiembre de 2024 que resultaron en órdenes judiciales preliminares y permanentes contra la versión anterior de la prueba RaDaR® de NeoGenomics. Natera está buscando remedios completos, incluida la reparación cautelar, contra la oferta actual de la prueba RaDaR® de NeoGenomics.
네이테라(NASDAQ: NTRA)는 네오제놈믹스에 대한 특허 침해 소송을 확대하여 미국 특허 제 11,319,596호를 사건에 추가했습니다. 노스캐롤라이나 중부 지방법원은 2024년 12월 10일 네이테라의 요청을 승인했습니다. 개정된 고소장은 이제 '596 특허와 이전에 주장된 '454 특허를 모두 포함하고 있으며, 네오제놈믹스의 분자 잔여병에 대한 수정된 RaDaR® 테스트의 침해를 주장합니다. 이번 법적 조치는 2023년 12월 및 2024년 9월의 이전 법원 판결 이후에 이루어진 것으로, 이는 네오제놈믹스의 이전 버전 RaDaR® 테스트에 대한 예비 및 영구 금지 명령을 초래했습니다. 네이테라는 네오제놈믹스의 현재 RaDaR® 테스트 제공에 대해 강력한 구제를 추구하고 있습니다.
Natera (NASDAQ: NTRA) a élargi sa poursuite pour violation de brevet contre NeoGenomics en ajoutant le brevet américain n° 11,319,596 à l'affaire. Le tribunal de district du district central de Caroline du Nord a accordé la demande de Natera le 10 décembre 2024. La plainte modifiée inclut maintenant à la fois le brevet '596 et le brevet '454 préalablement affirmé, alléguant une violation par le test RaDaR® modifié de NeoGenomics pour la maladie résiduelle moléculaire. Cette action en justice fait suite à des décisions judiciaires antérieures en décembre 2023 et septembre 2024 qui ont abouti à des injonctions préliminaires et permanentes contre la version précédente du test RaDaR® de NeoGenomics. Natera cherche à obtenir des recours complets, y compris une mesure d'injonction, contre l'offre actuelle du test RaDaR® de NeoGenomics.
Natera (NASDAQ: NTRA) hat seine Klage wegen Patentverletzung gegen NeoGenomics erweitert und die US-Patentschrift Nr. 11,319,596 in den Fall aufgenommen. Das Bezirksgericht für den Mittleren Distrikt von North Carolina genehmigte am 10. Dezember 2024 den Antrag von Natera. Die geänderte Klage umfasst nun sowohl das Patent '596 als auch das zuvor geltend gemachte Patent '454 und erhebt Ansprüche auf eine Verletzung durch NeoGenomics’ modifiziertem RaDaR®-Test für molekularen Restkrankheit. Diese rechtlichen Schritte folgen früheren Gerichtsurteilen im Dezember 2023 und September 2024, die zu vorläufigen und dauerhaften einstweiligen Verfügungen gegen die vorherige Version des RaDaR®-Tests von NeoGenomics führten. Natera strebt umfassende Abhilfemaßnahmen, einschließlich einer einstweiligen Verfügung, gegen das derzeitige Angebot des RaDaR®-Tests von NeoGenomics an.
- Successful expansion of patent infringement lawsuit with additional patent
- Previous court victories with preliminary and permanent injunctions against competitor's earlier product
- Strong legal position to protect intellectual property rights
- Ongoing legal expenses from patent litigation
Insights
Amended complaint asserts infringement of
On December 10, 2024, the District Court for the Middle District of
Natera asserts infringement of the ’596 and ’454 patents by the new version of NeoGenomics’ RaDaR® test, which tests for molecular residual disease. This follows a December 2023 preliminary injunction and September 2024 permanent injunction ordered by the District Court of NeoGenomics’ previous version of its RaDaR® test.
Natera is seeking full remedies against NeoGenomics’ current RaDaR® test offering, including injunctive relief.
About Natera
NateraTM is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, or the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217859445/en/
Investor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com
Source: Natera, Inc.
FAQ
What new patent did Natera (NTRA) add to its lawsuit against NeoGenomics?
How many patents is Natera (NTRA) asserting against NeoGenomics' RaDaR test?
What previous legal actions has Natera (NTRA) won against NeoGenomics' RaDaR test?
What remedies is Natera (NTRA) seeking in its expanded patent lawsuit?
